These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 25831756)

  • 1. [Anti-EGFR antibodies].
    Takahashi M
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():219-23. PubMed ID: 25831756
    [No Abstract]   [Full Text] [Related]  

  • 2. [Skin disorders].
    Uhara H
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():450-3. PubMed ID: 25831801
    [No Abstract]   [Full Text] [Related]  

  • 3. The efficacy of "Abound™," a nutritional supplement containing L-glutamine, L-arginine, citric acid, and calcium HMB, for skin disorders that developed as adverse drug reactions to anti-EGFR antibody preparation administration: pilot study.
    Matsuhashi N; Takahashi T; Tanahashi T; Matsui S; Sasaki Y; Tanaka Y; Okumura N; Yamaguchi K; Osada S; Yoshida K
    Int J Colorectal Dis; 2016 May; 31(5):1055-1057. PubMed ID: 26377336
    [No Abstract]   [Full Text] [Related]  

  • 4. Mechanisms of cutaneous toxicities to EGFR inhibitors.
    Lacouture ME
    Nat Rev Cancer; 2006 Oct; 6(10):803-12. PubMed ID: 16990857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine.
    García B; Neninger E; de la Torre A; Leonard I; Martínez R; Viada C; González G; Mazorra Z; Lage A; Crombet T
    Clin Cancer Res; 2008 Feb; 14(3):840-6. PubMed ID: 18245547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Management of cutaneous adverse events induced by molecularly-targeted drugs].
    Nakahara T
    Fukuoka Igaku Zasshi; 2014 Sep; 105(9):175-81. PubMed ID: 25639024
    [No Abstract]   [Full Text] [Related]  

  • 7. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study.
    Tejpar S; Piessevaux H; Claes K; Piront P; Hoenderop JG; Verslype C; Van Cutsem E
    Lancet Oncol; 2007 May; 8(5):387-94. PubMed ID: 17466895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted therapy for colorectal cancer resistance to EGF receptor antibodies and new trends.
    Katsios C; Ziogas DE; Roukos DH; Baltogiannis G
    Expert Rev Gastroenterol Hepatol; 2013 Jan; 7(1):5-8. PubMed ID: 23265143
    [No Abstract]   [Full Text] [Related]  

  • 9. [Anti-vascular endothelial growth factor antibody].
    Kumagai H; Kusaba H; Baba E
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():229-34. PubMed ID: 25831758
    [No Abstract]   [Full Text] [Related]  

  • 10. Skin moisturization for xerosis related to targeted anticancer therapies.
    Gisondi P; Girolomoni G
    J Am Acad Dermatol; 2015 Jul; 73(1):e33. PubMed ID: 26089072
    [No Abstract]   [Full Text] [Related]  

  • 11. Reply to: "Skin moisturization for xerosis related to targeted anticancer therapies".
    Valentine J; Belum VR; Duran J; Ciccolini K; Schindler K; Wu S; Lacouture ME
    J Am Acad Dermatol; 2015 Jul; 73(1):e35-6. PubMed ID: 26089073
    [No Abstract]   [Full Text] [Related]  

  • 12. [Adverse drug reactions induced by molecular target therapy].
    Kano Y
    Arerugi; 2007 Dec; 56(12):1485-91. PubMed ID: 18195551
    [No Abstract]   [Full Text] [Related]  

  • 13. B-cell epitope peptide vaccination targeting dimer interface of epidermal growth factor receptor (EGFR).
    Zhu L; Zhao L; Wu M; Chen Z; Li H
    Immunol Lett; 2013 Jun; 153(1-2):33-40. PubMed ID: 23871733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity.
    Guo XF; Zhu XF; Shang Y; Zhang SH; Zhen YS
    Clin Cancer Res; 2010 Apr; 16(7):2085-94. PubMed ID: 20332319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model.
    Reusch U; Sundaram M; Davol PA; Olson SD; Davis JB; Demel K; Nissim J; Rathore R; Liu PY; Lum LG
    Clin Cancer Res; 2006 Jan; 12(1):183-90. PubMed ID: 16397041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Skin care for cancer patients.
    Lacouture ME
    Clin Adv Hematol Oncol; 2012 Nov; 10(11):748-50. PubMed ID: 23271263
    [No Abstract]   [Full Text] [Related]  

  • 17. Pathology and management of dermatologic toxicities associated with anti-EGFR therapy.
    Fox LP
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):26-34. PubMed ID: 16736980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chemotherapeutic agents and electrolyte imbalance].
    Hashimoto Y; Yoshino T
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():426-31. PubMed ID: 25831796
    [No Abstract]   [Full Text] [Related]  

  • 19. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management.
    Hu JC; Sadeghi P; Pinter-Brown LC; Yashar S; Chiu MW
    J Am Acad Dermatol; 2007 Feb; 56(2):317-26. PubMed ID: 17141360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel monoclonal antibodies recognizing the active conformation of epidermal growth factor receptor.
    Ise N; Omi K; Miwa K; Honda H; Higashiyama S; Goishi K
    Biochem Biophys Res Commun; 2010 Apr; 394(3):685-90. PubMed ID: 20226763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.